Importantly, a publication has reported that the loss-of-function mutation in SPOP compromises ubiquitination-mediated PD-L1 degradation, thus increasing PD-L1 level and reducing the number of tumor-infiltrating lymphocytes in mouse tumors and in clinical prostate cancer specimens [36]. Here, SPOP is linked to prostate carcinoma.